Emergent BioSolutions (EBS) Other Accumulated Expenses (2018 - 2026)

Emergent BioSolutions' Other Accumulated Expenses history runs 9 years deep, the most recent figure standing at $8.0 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 27.93% year-over-year to $8.0 million; the TTM figure through Mar 2026 stood at $8.0 million (down 27.93% YoY), while the FY2025 annual figure was $10.8 million, down 50.68% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $8.0 million, down from $10.8 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $67.6 million in Q3 2024, with the low at $8.0 million in Q1 2026.
• The 5-year median for Other Accumulated Expenses is $24.1 million (2025), against an average of $25.3 million.
• The sharpest annual moves came in 2022 and 2024: Other Accumulated Expenses slumped 79.84% in 2022, then soared 76.96% in 2024.
• Emergent BioSolutions' Other Accumulated Expenses stood at $45.9 million in 2022, then declined by 28.76% to $32.7 million in 2023, then slumped by 33.03% to $21.9 million in 2024, then plunged by 50.68% to $10.8 million in 2025, then declined by 25.93% to $8.0 million in 2026.
• Business Quant data shows EBS's Other Accumulated Expenses at $8.0 million in Q1 2026, $10.8 million in Q4 2025, and $24.1 million in Q3 2025.